Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 1.61MM shares of Galecto Inc (GLTO). This represents 5.9% of the company.
In their previous filing dated August 2, 2023 they reported 2.24MM shares and 8.30% of the company, a decrease in shares of 28.28% and a decrease in total ownership of 2.40% (calculated as current – previous percent ownership).
Analyst Price Forecast Suggests 1,660.90% Upside
As of August 2, 2023, the average one-year price target for Galecto is 12.24. The forecasts range from a low of 6.06 to a high of $17.85. The average price target represents an increase of 1,660.90% from its latest reported closing price of 0.70.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Galecto is 3MM. The projected annual non-GAAP EPS is -1.86.
What is the Fund Sentiment?
There are 38 funds or institutions reporting positions in Galecto. This is an increase of 4 owner(s) or 11.76% in the last quarter. Average portfolio weight of all funds dedicated to GLTO is 0.03%, an increase of 51.92%. Total shares owned by institutions increased in the last three months by 9.85% to 10,112K shares. The put/call ratio of GLTO is 0.77, indicating a bullish outlook.
What are Other Shareholders Doing?
Novo Holdings A holds 2,498K shares representing 9.21% ownership of the company. No change in the last quarter.
Cormorant Asset Management holds 1,020K shares representing 3.76% ownership of the company. No change in the last quarter.
Soleus Capital Management holds 1,000K shares representing 3.69% ownership of the company. In it’s prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
MAI Capital Management holds 245K shares representing 0.90% ownership of the company. In it’s prior filing, the firm reported owning 255K shares, representing a decrease of 4.15%. The firm increased its portfolio allocation in GLTO by 13.58% over the last quarter.
Laurion Capital Management holds 191K shares representing 0.70% ownership of the company. No change in the last quarter.
Galecto Background Information
(This description is provided by the company.)
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company’s team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases.
This article originally appeared on Fintel
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
